Recombinant human factor ix and use thereof
AssigneeShu-Wha Lin
InventorsShu-Wha Lin, Chia-Ni Lin, Hua-Lin Wu, Guey-Yueh Shi
Life of this patent
Estimating the term…
Abstract
The present invention aims at converting factor IX into a molecule with enhanced activity which provides an alternative for replacement therapy and gene therapy for hemophilia B. Using recombinant techniques, factor IX with replacement at positions 86, 277, and 338 exhibits better clotting activity than recombinant wild type factor IX.
Claims19
A recombinant human factor IX protein having substitution of amino acid residue of SEQ ID No. 7 at amino acid position selected from the group consisting of 86, 277 and 338, provided that the substitution at amino acid position 338 is excluded.
An isolated nucleic acid encoding a recombinant human factor IX protein having nucleic acid sequence shown in SEQ ID NO. 9, 10, 11, 12, 13 or 14.
Dependencies are inferred from the claim text.